All In Biotech

Drug Trial Radar · NCT05752461

SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

A Multicenter, Randomized, Active-comparator-controlled Phase 2 Clinical Trial to Assess the Efficacy and Safety of a Single Subcutaneous Injection of SHR-2004 in Patients Undergoing Elective Unilateral Total Knee Arthroplasty

Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 353 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

353

Actual

Start

Apr 12, 2023

Primary completion

Apr 12, 2024

Study completion Jun 25, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 2, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of SHR-2004 in preventing venous thromboembolism after elective unilateral total knee arthroplasty

Conditions

  • Prevention of Venous Thromboembolism After Knee Arthroplasty

Interventions

  • SHR-2004 injectionDrug

    low dose subcutaneous injection once

  • SHR-2004 injectionDrug

    medium dose subcutaneous injection once

  • SHR-2004 injectionDrug

    high dose subcutaneous injection once

  • Enoxaparin sodium injectionDrug

    40 mg administered as subcutaneous injection once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of composite endpoint consisting of asymptomatic DVT as detected by mandatory bilateral CT venography, confirmed symptomatic DVT, non-fatal PE and all-cause death(Primary efficacy outcome)Time frame: Day 12
  2. Incidence of composite endpoint of major and clinically relevant non-major bleeding(Primary safety outcome)Time frame: Day 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital Central South University

    Changsha, Hunan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.